R. Duchnowska et at Correlation Between Quantitative Her-2 Protein Expression and Risk for Brain Metastases in Her-2 Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy The Oncologist 2012 17:26-35 online here
YS. Yap et al Brain Metastases in Asian Her-2 Positive Breast Cancer Patients: Anti-HER2 Treatments and Their Impact on Survival British Journal of Cancer 2012 107:1085-1077
J. Ro et al Clinical Outcomes of HER2-Positive metastatic breast cancer Patients with Brain Metastasis Treated with Lapatinib and Capecitabine: an Open-Label Expanded Access Study in Korea Biomedcentral Central Cancer 2012 12:332
A. Mehta et al Therapeutic Approaches for HER2-Positive Brain Metastases: Circumventing the Blood-Brain Barrier Cancer Treatment Review 2012
S. Sutherland et al Treatment of HER2-Positive Metastatic Breast Cancer with Lapatinib and Capecitabine in the Lapatinib Expanded Access Programe, including Efficacy in Brain Metastases-the UK Experience British Journal of Cancer 2010 (102):995-102
M. Abboud et al Complete Response of Brain Metastases from Breast Cancer Overexpressing Her-2/neu to Radiation and Concurrent Lapatinib and Capecitabine The Breast Journal 2010 Vol.16:6
A. Braen A 4-Week Intrathecal Toxicity and Pharmacokinetic Study in Cynomolgus Monkeys International Journal Toxicology May 2010 29(3):259-67
T. Pienkowski et al Trastuzumab (Herceptin) Treatment in Patients with Breast Cancer and Metastatic CNS Disease Annals of Oncology May 2010 21(5):917-24
S Dawood et al Prognostic Factor of Survival in the Trastuzumab (Herceptin) Era among Women with Breast Cancer amd Brain Metastases who Receive Whole Brain Radiotherapy: a Single-insitution Review Cancer Jul 1 2010 116(13):3084-92
A. Niwinska et al The Effect of Early Detection of Occult Brain Metastases in HER2-positive Breast Cancer Patients on Survival and Cause of Death International Journal of Radiation Oncology Biology Physics Jul 15 2010 77(4):1134-9
G. Tomasello et al Brain Metastases in HER2-positive Breast Cancer: the Evolving Role of Lapatinib (Tykerb) Critical Review of Oncology Hematology Aug 2010 75(20):110-21
G. Metro et al Clinical Outcome of Patients with Brain Metastases from Her2-Positive Breast Cancer treated with Lapatinib (Tykerb) and Capecitabine (Xeloda) Annals of Oncology Aug 19 2010
S. Sutherland et al Treatment of HER-2 Positive Metastatic Breast Cancer with Lapatinib and Capecitabine in the Lapatinib (Tykerb) Expanded Access Programme, Including Efficacy in Brain Metastases-the UK Experience British Journal Cancer Mar 16 2010 102(6): 995=1002
M. Melisko New Challenges and Opportunities in the Management of Brain Metastases in Patients with Erb2-Positive Metastatic Breast Cancer Nat Clin Pract Oncol Jan 2009 6(1):25-33
B. Pestalozzi Brain Metastases and subtypes of Breast Cancer Annals of Oncology April 2009 20(4): 803-5 FREE FULL TEXT
M. Colozza et al Extended Survival of a Her-2 Positive Metastatic Breast Cancer Patient with Brian metastatses also Treated with Intrathecal Trastuzumab (Herceptin) Cancer Chemothery Pharmacol May 2009 63(6):1157-9
B. Leyland-Jones Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous systems Metastases Journal of Clinical Oncology Nov 2009 27(31):5278-86
H. Stemmler, K Mengele, V. Heinemann Intrathecal Trastuzumab (Herceptin) and Methotrexate for Meningeal Carcinomatosis in HER2-Overexpressing Metastatic Breast Cancer: A Case Report Anti Cancer Drugs, 2008; 19:832-836
B. Nam, S. Kim, J. Ro et al Breast Cancer Subtypes and Survival in Patients with Brain Metastases Breast Cancer Research, Feb. 28, 2008
A. Eichler, I. Kuter, J. Henson et al Survival in Patients With Brain Metastases From Breast Cancer: The Importance of HER-2 Status Cancer March 2008
M. Melisko, D. Moore, H. Rugo et al Brain Metastases in Breast Cancer: Clinical and Pathologic Characteristics Associated with Improvements in Survival Journal of Neurooncology. 2008; 88:359-365
I. Park, J. Ro, B. Nam et al Trastuzumab Treatment Beyond Brain Progression in HER2-Positive Metastatic Breast Cancer Annals of Oncology. July 2008 (Epub ahead of print)
S. Fromm, R. Bartsch, K. Dieckmann et al Factors Influencing the Time to Development of Brain Metastases in Breast Cancer The Breast, 2008; 1-5
R. Bartsch, A. Rottenfusser, G. Steger et al Trastuzumab Prolongs Overall Survival in Patients with Brain Metastases from Her2 Positive Breast Cancer Journal of Neurooncology, 2007; 85:311-317
Y. Than, K. Sexton, R. Elledge et al Primary Breast Cancer Phenotypes Associated with Propensity for Central Nervous System Metastases Cancer, July 2006
D. Hicks, S. Short, R. Weill et al Breast Cancers with Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress Her2 or EGFR American Journal of Surgery and Pathology, Sept. 26, 2006; 30:9
S. Gori, S. Rimondini, V. De Angelis et al Central Nervous System Metastases in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors The Oncologist, July 2007; 12 (7): 766-773 (free full text).
N. Lin and E. Winer Brain Metastases: The HER2 Paradigm Clinical Cancer Research, March 15, 2007; 13 (6).
Z. Gambos, R. Sinha, J. Hanson et al Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis after Newly Diagnosed Breast Cancer Journal of Clinical Oncology, December 20, 2006; 24 (36): 5658-5663.
D. Kirsch and J. Loeffler Survival after Brain Metastases from Breast Cancer in the Trastuzumab (Herceptin) Era Journal of Clinical Oncology, March 20, 2005; 23 (9): 2114-2116 (free full text).
H. Burstein, G. Lieberman, D. Slamon et al Isolated Central Nervous System Metastases Treated with HER2-Overexpressing Advanced Breast Cancer Treated with First-line Trastuzumab (Herceptin)-Based Therapy Annals of Oncology, September 8, 2005; 16: 1772-1777 (free full text).
A. Clayton, S. Danson, S. Jolly et al Incidence of Cerebral Metastases in Patients Treated with Trastuzumab (Herceptin) for Metastatic Breast Cancer British Journal of Cancer, July 20, 2004; 91: 649-643.
N. U. Lin, V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, D. Laessig, H. RochÃ©, D. Zembryki, C. R. Oliva, E. P. Winer, EGF105084 Study Group. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 1012 (Slide presentation online).
N. U. Lin, L. A. Carey, M. C. Liu, J. Younger, S. E. Come, E. Bullitt, A. D. Van Den Abbeele, X. Li, F. H. Hochberg, E. P. Winer. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 503. (Slide presentation online).
C.E. Geyer, J. Forster, D. Lindquist, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine, December 28, 2006, number 26, 355:2733-2743 (full text with free registration).